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Abstract  
Background and objectives. Methadone is a -opioid agonist widly used for pain treatment 
and for detoxification or maintenance treatment in opioid addiction. It has been shown to 
exhibit large pharmacokinetic variability and concentration-QTc relationships. In this study we 
investigated the relative influence of genetic polymorphism and of other variables on the 
dose-concentration-QTc relationship. 
Patients and methods. A population model for methadone enantiomers in 251 opioid 
dependant patients was developed using non-linear mixed effect modeling (NONMEM®). 
Various models were tested to characterize the pharmacokinetics of (R)- and (S)-methadone 
and the pharmacokinetic-pharmacodynamic relationship, while including demographics, 
physiological conditions, comedications and genetic variants as covariates. Model-based 
simulations were performed to assess the relative increase in QTc with dose upon 
stratification based on genetic polymorphism. 
Results. A two-compartment model with first-order absorption and lag time provided the best 
model fit for (R)- and (S)-methadone pharmacokinetics. (S)-methadone clearance was 
influenced by CYP2B6 activity, ABCB1 3435C>T and α-1 acid glycoprotein level while that of 
(R)-methadone by CYP2B6 activity, POR*28 and CYP3A4*22. A linear model described the 
methadone concentration-QTc relationship, with a mean QTc increase of 9.9ms and 19.2ms 
per 1000ng/ml of (R)- and (S)-methadone, respectively. Simulations with different methadone 
doses up to 240mg/day showed that <1% of patients would present QTc above 470ms, but 
might reach 6-10% in patients with a genetic status associated with a decreased methadone 
elimination at doses exceeding 240 mg/day.  
Conclusion. Risk factor assessment, electrocardiogram monitoring, and therapeutic drug 
monitoring are beneficial to optimize treatment in methadone patients, especially for those 
who have low levels despite high methadone doses or who are at risk of overdosing. 
Key points 
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 This study show that methadone enantionmers’ concentration profiles are very 
variable and affect the QTc interval, which partially dependent on the patient’s genetic 
status. 
 QTc intervals predicted in this study according to patients’ genetic factors confirm the 
need for electrocardiogram monitoring and arrhythmia risk factor assessment to 
improve methadone safety. 
 Plasma methadone concentrations measurements by therapeutic drug monitoring 
may be beneficial to guide practitioners’ dosing decisions, especially for those 
patients who have low levels despite high methadone doses or who are at risk of 
overdosing  
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Introduction 
Methadone is a -opioid agonist used for more than 30 years for pain treatment, and for 
detoxification or maintenance treatment in opioid addiction. The World Health Organization 
has introduced this drug in the list of essential medicines in 2005 [1]. They are however 
numerous case reports, retrospective analyses and observational studies describing QT 
prolongation and torsade de pointes (TdP) in patients under methadone treatment, especially 
in those receiving high to very high doses of methadone [2].  
Methadone is mainly administered as a chiral mixture of (R,S)-methadone. However the -
opioid receptor activation is mostly due to (R)-methadone [3], while (S)-methadone is 3.5 
times more potent in blocking the cardiac hERG channel, the latter being therefore at higher 
risk for prolonging the QT interval [4, 5]. The higher potential of the (S)-enantiomer to block 
the hERG channel was confirmed in opioid dependant patients in maintenance treatment in 
whom replacement of (R,S)-methadone by (R)-methadone led to a significant decrease of 
QTc values[6]. However, as (R)-methadone is currently available in only a few countries, the 
prescription of (R,S)-methadone should in no way be limited when clinically indicated and 
well monitored. 
The variability in methadone concentrations and effect relationship is very large. 
Pharmacokinetic variability has been attributed to cytochrome P450 (CYP) isoenzymes, 
mainly CYP3A4 and CYP2B6, and to P-glycoprotein (P-gp encoded by the ATP-binding 
cassette sub-family B member 1 (ABCB1) gene), the activities of which are genetically and 
environmentally determined [7]. In addition, stereoselective CYP2B6-mediated metabolism of 
(S)-methadone, as evidenced by previous in vitro/in vivo data [8-11], induces higher plasma 
concentrations of (S)- than (R)-methadone in CYP2B6 slow metabolizers [12, 13]. The 
CYP2B6*6/*6 genotype represents about 6% of Caucasians and African-Americans, who 
could thus be at higher risk of developing cardiotoxicity. Cytochrome P450 reductase (POR) 
plays a major role in drug metabolism as all microsomal CYP receive electrons from 
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nicotinamide adenine dinucleotidephosphate (NADPH) through POR [14]. A large number of 
POR SNPs have now been described, which might influence CYP activities and thus drug 
metabolism [14]. Although stereoselective pharmacokinetics of methadone, genetic 
influences on (R)- and (S)- methadone concentration and concentration-effect relationships 
have been already explored [15-17], the relative influence of genetic polymorphism and of 
other variables on the dose-concentration-QTc relationship remains to be investigated. 
The objectives of the study were to characterize the population pharmacokinetics of (R)- and 
(S)-methadone, to identify genetic and non-genetic sources of variability and to relate 
methadone concentrations to QTc interval in a cohort of opioid dependant patients in 
methadone maintenance treatment. The model served to simulate (R)- and (S)-methadone 
concentration-QTc interval at various dosage regimen of methadone according to the genetic 
status in order to quantify the expected increase of QTc in the different groups. 
Materials and methods 
Study population 
Plasma (R)- and (S)-methadone levels, measured by liquid chromatography coupled with 
mass spectroscopy [18], and QTc measurements were obtained from 244 opioid-dependent 
patients in 5 methadone-dispensing centers in Geneva, Lausanne, Bern, and Montreux, 
Switzerland [7]. Steady-state concentration samples with matched QTc interval 
determinations (Fridericia-corrected) were collected around peak (4h) and/or trough (24h) 
drug levels. In addition, seven opioid-dependent patients taking part in an interaction study 
[19] provided 11 (R)- and (S)-methadone concentrations per patient, measured by liquid 
chromatography coupled with ultraviolet detection [20] , collected between 0.5 and 23 h post 
dose under steady-state conditions. Mean (± SD) methadone dose was 123 (± 75) mg (range 
3-400 mg) and was given once or twice daily. The ethics committees of the corresponding 
centers approved the project and all participants gave written informed consent for genetic 
testing.  
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Analytical method 
Genotyping 
Genomic DNA was extracted from EDTA blood samples with the FlexiGene DNA Kit 
(Qiagen, Hombrechtikon, Switzerland). All the SNPs, with the exception of CYP2D6*5, 
CYP2D6*xN and CYP3A4*22, were detected by real-time polymerase chain reaction (PCR) 
with the use of 5’-nuclease allelic discrimination assays (ABI PRISM 7000 Sequence 
Detection System, Applied Biosystems, Rotkreuz, Switzerland) with primers and probes 
obtained from Applied Biosystems. The tested genetic polymorphisms are listed in Table 2 
and were analyzed as previously described except for CYP3A4*22 [7, 21-23]. CYP3A4*22 
was genotyped with a custom Illumina iSelect genotyping array on an iScan equipped 
platform (Illumina, San Diego, California). Quality control was assessed by the call rate 
(>96%), GC score (>0.15) and matched gender. Genetic data was called by using 
GenomeStudio software (version 2011.1, Illumina, San Diego, California).  
Model-based pharmacokinetic modeling 
The model building process consisted of: (i) a population pharmacokinetic model for (R)- and 
(S)-methadone using rich sampling data; (ii) an extension to the whole dataset while taking 
into account potential influencing variables; (iii) a simultaneous pharmacokinetic-
pharmacodynamic (PK-PD) analysis for the concentration-QTc interval relationship 
evaluation. 
Structural models  
A stepwise procedure was used to find the models that fitted methadone data at best. The 
final pharmacokinetic model was a two-compartment model with first-order absorption and 
lag time for both drugs. The estimated parameters are clearance (CL), volume of distribution 
of the central compartment (Vc), volume of distribution of the peripheral compartment (Vp), 
intercompartmental clearance (Q), absorption rate constant (ka) and lag-time (Tlag). Since 
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methadone was only administered orally, CL, Vc, Vp and Q represent apparent values.  
Methadone was given as a racemic mixture composed of 50:50 of both enantiomers, and 
methadone dose was reduced by half by fixing the relative bioavailability to 0.5 for the 
separate analysis of each moiety. Exponential errors following a lognormal distribution with 
mean zero and variance 2 were assumed for the description of the interindividual variability. 
A proportional error model was used to model the residual variability with mean zero and 
variance 2. Methadone elimination half-lives (t½ and t½, volume of distribution at steady-
state (Vdss) and mean absorption time (MAT= 1/ka + lag-time) were derived using classical 
equations. 
Covariate models 
The available covariates were demographics (sex, body weight, race), physiopathological 
(α1-glycoprotein, albumin), environmental (smoking, co-medications) (Table 1) and tested 
genetic polymorphisms (Table 2). The potential influence of available covariates were 
explored graphically and then tested for significance into the model. The typical value of a 
parameter was modeled to depend on a covariate (continuous variables centered on the 
mean; categorical covariates being coded as indicator variables 0 or 1), testing linear and 
non-linear relationships, as appropriate. Comedications were classified into inducers or 
inhibitors of CYP3A4 and CYP2B6 and inhibitors of CYP2D6 [24-27] (Table 1). 
Comedications potentially affecting the QT intervals were categorized as drugs with a known, 
possible or conditional risk of torsade de pointes according to CredibleMeds.org [28] and 
patients were grouped according to their highest risk comedication. Genetic variants were 
classified into 3 groups: reference allele (Ref), heterozygote (Het) loss/decrease/gain of 
function (LOF/DOF/GOF) and homozygote (Hom) LOF/DOF/GOF variants. LOF and DOF 
alleles will be defined as DOF thereafter. An activity score for CYP2B6 was derived to test for 
the effect of a combination of CYP2B6*6, *5 and *11 alleles. In this model, a score of 2 was 
attributed to fully functional alleles CYP2B6*1/1, *5/*5, *1/*4, *1/*5, *4/*5, a score of 1 to 
CYP2B6*1/*11, *1/*6, *4/*6, *5/*6 and a score of 0 to CYP2B6*6/*6 and *6/*11. The 
 	 Page	9		
relationship between methadone CL and the number of functional alleles was first tested 
using a rich model (eq.1) and competing models that accounted for gene effect as a function 
of the number of functional alleles using linear (eq.2), power (eq.3) and square root (eq.4) 
relationships with either additive or proportional (not shown) effect, as follows: 
 (1) 
 (2) 
 (3) 
 
 (4) 
where n =1, 2 represents the functional score and 1 the average contribution per active 
allele above the clearance level of Hom DOF individuals (CL0). The joint influence of 
functional alleles on methadone CL was first tested using pair-wise conjunction of CYP2B6 
with the other CYP alleles, to finally build up the model including all influent genetic variants. 
The impact of functional alleles on methadone CL was further explored using the dominant 
(Hom/Het DOF vs. Ref alleles) and recessive (Hom DOF vs. Het DOF/Ref alleles) models. 
The investigation of the joint influence of CYP2B6 and ABCB1 3435C>T alleles is shown as 
an example. The richest model was: 
 (5) 
where here CL0 is CL in individuals Hom DOF for both genes and Iij is an indicator variable 
that takes the value of 1 if the individual carries the CYP2B6 ith genotype and the ABCB1 
3435C>T jth genotype and is “0” otherwise, and each ij estimate the absolute change in CL 
among the different genotypic groups. The following competing models were evaluated:  
 (6) 
 (7) 
CL CL0  (11I1)  (12I 2 )
nCLCL  10 
nCLCL 10 
nCLCL 10 
CL CL0 01I 01 02I 02 10I10 11I11 12I12 20I 20 21I 21 22I 22
CL CL0 1  p   (2I1 3I 2 )
CL CL0 1  p  (2 n)
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 (8) 
where p indicates the functional score for CYP2B6 and q the score for ABCB1 3435C>T. In 
eq.6, the contribution of ABCB1 3435C>T ( is investigated using all genetic groups on 
CYP2B6 polymorphism and in reduced models and testing linear (eq.7) and square root 
functions (eq.8) for both genes.  
Concentration-QTc modeling 
The relationship between methadone concentrations and the Fridericia heart-rate corrected 
QTc [29] interval were explored using linear and log-linear models of the general form: 
 ܳܶܿ௜௝ ൌ ܫ݊ݐ݁ݎܿ݁݌ݐ௜ ൅ ݈ܵ݋݌݁௜ ∙ ܥ݋݊ܿ௜௝ ൅ ߝ௜௝ (9) 
where Slopei and Intercepti are the slope and the intercept for the ith individual and QTcij and 
is the Fridericia’s corrected QT interval and Concij methadone concentration for the ith 
individual and the jth time point. The residual variabilityij, was included assuming an additive 
error with mean zero and variance 2 and an interindividual variability on the slope and 
intercept was tested assuming a normal distribution with mean zero and variance 2. 
Available potentially influencing factors on the QTc interval were sex, potassium and calcium 
levels, comedications affecting the QTc interval and were included in the model using linear 
functions. 
Parameter Estimation and Selection  
NONMEM® [30](version 7.2, NM-TRAN, version II) was used with the FOCE INTERACTION 
method to fit the data. The minimum objective function value (∆OF) provided by NONMEM®, 
(-2 log likelihood, approximate 2 distribution) was used to discriminate between hierarchical 
models using the log likelihood test. A model was considered superior to another nested 
model when the OFV value was reduced by at least 3.84 points (p< 0.05). Covariate analysis 
comprised forward selection of influential factors followed by backward deletion and were 
qpCLCL  210 
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retained in the final model at the statistical level of p < 0.01. The most appropriate model for 
the concentration-QTc relationship was selected based on Akaike information criteria and the 
log likelihood test for the influence of covariates. Model assessment was based on diagnostic 
plots along with the measure of the standard errors, the correlation matrix of parameter 
estimates, the size of residual errors and eta-shrinkage. 
Model validation 
The stability and the performance of the final population pharmacokinetic model were 
validated by the bootstrap method using 2000 bootstrap resampling with replacement (Perl-
speaks-NONMEM version 3.2.4 (http://psn.sourceforge.net/)).  The median and the 95% 
confidence interval of each parameter obtained with the bootstrapped data were compared to 
the parameters of original dataset. In addition, simulations were performed in 1000 to predict 
the 2.5th, 50th and 97.5th percentiles of the concentrations and QTc intervals and compared 
with observed data. The figures were generated using GraphPad Prism (Version 4.00 for 
Windows, GraphPad Software, San Diego California USA, (www.graphpad.com). 
Simulations 
Simulations for (R)- and (S)-methadone plasma and QT interval were performed in 1000 
individuals for doses ranging from 80 mg to 280 mg once daily at steady-state. The volume 
of distribution of (S)-methadone was fixed for a typical patient with a median AAG level of 
0.97 g/L. A “lowest” CL and “best” CL value were calculated for (R)- and (S)-methadone 
stratified according to the genetic status. Average QT interval predictions with the 95% 
prediction intervals (PI95%) for each dosage regimen were retrieved. In addition, the 
percentage of patients with absolute QT above the thresholds of >450 ms and > 470 ms 
associated with an increased risk of cardiotoxicity was derived. 
Prediction of (R,S)-methadone plasma concentration threshold for QTc 
prolongation risk 
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Receiver operating characteristic (ROC) analyses and graph were performed using 
GraphPad Prism (Version 6.05 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com) to predict a threshold of (R,S)-methadone plasma concentration for 
increased risk of QTc above 450 ms. 
Results  
A total of 504 (R)- and (S)-methadone plasma concentrations and 317 QTc intervals were 
used for the analysis. A summary of the population characteristics and of the tested genetic 
polymorphisms are presented in Tables 1 and 2. 
Population Pharmacokinetic Analysis 
Structural model for (R)- and (S)-methadone. Analyses from 7 individuals with rich 
sampling showed that a two-compartment model with first order absorption fitted the data 
better than a one-compartment model for both enantionmers (∆OF>-23;p<0.001); the 
addition of a lag time significantly improved the fit for both compounds (∆OF>-34;p<0.001). 
In addition to CL, assignment of an interindividual variability on Ka improved the fit for (R)- 
(∆OF=- 43;p<0.001) and (S)-methadone (∆OF=-37;p<0.001), as well as on Q for the latter 
(∆OF=-7;p<0.01). This model adequately fitted (R)- and (S)-methadone concentrations of the 
whole population. The lack of drug level measurements during the absorption phase 
prevented from a precise estimation of Ka; this parameter and the lag time were thus fixed to 
the estimates from the rich data analysis. Addition of an interindividual variability on Vc and 
Q (∆OF>-34;p<0.001) improved the description of both enantiomers’ data, with a correlation 
between CL and Vc (∆OF>-12;p<0.01). Allowing Ka and the peripheral volume of distribution 
(Vp) to vary did not improve the model fit (∆OF>-1.2).  
Covariate modeling on (S)-methadone. Among the non-genetic covariates, only α-1 acid 
glycoprotein (AAG) concentrations influenced Vc (∆OF=-12.8;p<0.001), indicating a 25% 
increase in volume upon AAG doubling.  
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Univariate analyses testing the influence of genetic polymorphisms revealed that CYP2B6*6 
had a marked impact on (S)-methadone elimination (∆OF=-14.0,p<0.001), with an estimated 
CL of 10.6 l/h, 9 l/h and 6.6 l/h in Ref, Het decrease of function allele (DOF) and Hom DOF 
patients, respectively. A trend for an influence of the CYP2B6 rs2279344 polymorphism was 
found (∆OF=-3.8,p=0.051), suggesting a 14% decrease in (S)-methadone CL in Hom DOF 
carriers compared to the other groups. CYP2B6*11 (∆OF=-2.4;p=0.12), and CYP2B6*5 
(∆OF=-0.7;p=0.4) did not show any influence. The use of an activity score combining 
CYP2B6*6, *5 and *11 improved the fit (∆OF=-20.4;p<0.001), providing very close estimates 
of CL to the model including CYP2B6*6 solely, and was retained for further analyses. The 
relationship between CL and the number of CYP2B6 functional alleles could adequately be 
described by a square root model (eq.4). This model estimated a CL of 6.2 l/h in Hom DOF 
patients that increased by 3.1 ∙ √݊ (n=number of functional allele). Polymorphism in POR*28 
showed a significant influence on CL (∆OF=-4.1;p<0.05); a 20% increase in (S)-methadone 
CL in Hom gain of function allele (GOF) (POR*28 TT) compared to Ref and Het GOF 
patients was observed. CYP3A4*22 Het DOF was associated with a non-significant 15% 
decrease in (S)-methadone CL (∆OF=-3,p=0.08). Variations in the ABCB1 3435C>T (∆OF=-
5.9;p<0.05), 2677G>T/A (∆OF=-7;p<0.01), 61A>G (∆OF=-4.5;p<0.05) and 1199G>A (∆OF=-
9.2;p<0.01) significantly affected (S)-methadone CL. Patients carrying two variant alleles of 
these polymorphisms had a 15 to 30% higher methadone elimination compared to Het DOF 
and Ref patients. CYP3A5*3 did not show any influence on (S)-methadone CL (∆OF=-
2.4;p=0.12). No other genetic polymorphism showed any influence. 
Stepwise inclusion of the significant genetic variants in the multivariate analyses identified 
CYP2B6 activity score and ABCB1 3435C>T polymorphism as significant covariates on CL. 
Both allele influences were best captured using a square root model for CYP2B6 functional 
alleles with an additional influence of ABCB1 3435C>T for Hom DOF carriers of this gene 
(eq. 6). No statistical difference in CL between ABCB1 3435C>T Het DOF and Hom DOF 
stratified for CYP2B6 was observed, and both linear (eq. 7) and square root models (eq.8) 
described the data as well (∆OF< -0.7). All other significant allelic variants were correlated to 
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both genes and did not remain statistically significant. The influence of AAG levels on Vc was 
retained in the final model. This final model explained 4%, 16% and 7% of the interindividual 
variability on CL, Vc and Q, respectively. 
Covariate modeling on (R)-methadone. No non-genetic factors showed any influence on 
(R)-methadone disposition. Inclusion of CYP2B6*6 (∆OF=-7.0;p<0.01) and CYP2B6 activity 
score (∆OF=-7.5;p<0.01) improved the description of (R)-methadone elimination. These 
models estimated a CL of 10.4 l/h, 9.5 l/h and 8.0 l/h in Ref, Het DOF and Hom DOF 
patients, respectively. The use of a square root model according to the number of functional 
alleles fitted the data as well as the rich model, with a CL of 7.9 l/h in Hom DOF that 
increased by 1.7 ∙ √݊.  A significant influence of the CYP2B6 rs8192719 polymorphism was 
found (∆OF=-7.9; p<0.01), but not of the CYP2B6 rs2279344 (∆OF=-3.5;p=0.061). Variations 
in the POR*28 (∆OF=-7.1;p<0.01) and CYP3A4*22 (∆OF=-5.0;p<0.05) influenced the model 
fit, revealing an increase in CL by 14% in Het or Hom GOF carriers of POR*28 and a 
decrease of 22% in Het DOF CYP3A4*22 compared to the Ref groups. CYP3A5*3 did not 
show any influence on (R)-methadone CL (∆OF=0). No other genetic polymorphism showed 
any influence.  
The CYP2B6 activity score, POR*28 and CYP3A4*22 remained statistically significant in the 
multivariate analysis. CYP2B6 rs8192719 was not retained due to a strong linkage with 
CYP2B6*6. The joint effect of the three alleles was best fitted using an additive model (eq. 
6), with no further improvement while using competing models (eq. 7 or eq. 8). This final 
model explained 5%, 6% and 16% of the interindividual variability on CL, Vc and Q, 
respectively. 
 
Methadone concentration-QTc interval Analysis 
The concentration-QTc interval relationship was fitted using a linear model, with no difference 
observed using a log-linear model (∆OF<-1.83). The assignment of an interindividual 
variability on the intercept parameter improved significantly the fit (∆OF=-62 for (R)- and 
 	 Page	
15		
∆OF=-64 for (S)-Methadone;p<0.001), but no variability on the slope parameter was found 
(∆OF=0). A slightly non-significant higher intercept QTc level of about 3 ms was observed in 
women compared to men and no difference in slope was observed (∆OF>-2). Neither 
potassium, nor calcium levels significantly influenced the concentration-QTc relationship 
(∆OF>-1.3), nor did comedications at risk of QTc prolongation. The final population 
parameters are presented in Table 3. Goodness-of-fit plots are presented in Supplementary 
Figure 1. 
 
Model Validation 
The median parameter estimates obtained with bootstrap with the 95% confidence interval 
(CI) are presented in Table 3. The parameter estimates of the final population 
pharmacokinetic model lied within the 95% CI of the bootstrap results suggesting that the 
model was acceptable. The visual predictive check of the observed methadone 
concentrations versus time and the concentration-QTc plots is shown in Figure 1.  
 
Simulations 
Simulations of (R)- and (S)-methadone concentrations for 80 mg to 320 mg once daily 
assuming a “best” and “lowest” elimination of each enantiomer according to influencing 
genetic effects are shown in Figure 2. The probability of the QTC value being above the 450 
ms threshold is increased by 1.5 to 2 times depending on the genotypic status. Less than 4% 
of patients would present QTc above 450 ms at the dose levels below or equal to 160 mg 
daily, but this number might increase up to 10% for patients at doses exceeding 240 mg/day 
with a genetic status associated with a decreased methadone elimination, particularly 
observed for (S)-methadone. Less than 1% of patients would present QTc values above 470 
ms according to our model. 
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Prediction of (R,S)-methadone plasma concentration threshold for QTc 
prolongation risk 
The ROC analysis indicates that a plasma concentration of (R,S)-methadone above 656 
ng/ml is the best predictor for a QTc above 450 ms (Supplementary Figure 2; 
sensitivity=79%; specificity=68%; ROC AUC=0.69 േ 0.06; 95%CI=0.57-0.81, p=0.01). 
 
Discussion 
We developed a population pharmacokinetic-pharmacodynamic model for methadone in a 
cohort of opioid patients, and could quantify the relative contribution of genetic and non-
genetic factors affecting drug disposition, its consequences on the QTc interval and predict 
QTc increase according to dose and patients’ genetic status. 
Estimates of (R)- and (S)-methadone pharmacokinetic parameters are in good accordance 
with previous results [16, 17]. No demographic covariates showed any influence on these 
compounds’ kinetics, except for an influence of AAG on the volume of distribution of (S)-
methadone. The lack of influence of protein binding on (R)-methadone could be related to a 
lower protein binding of this enantiomer [31]. As expected, a marked interindividual variability 
in methadone pharmacokinetics was observed, even more pronounced for (S)-methadone. 
This large variability is typical of drugs that are metabolized by polymorphic enzymes such as 
CYP3A4 and CYP2B6. Few strongly interacting co-medications were taken by patients, thus 
reducing the power to detect any influence of comedications. Since CYP2D6 seems only 
moderately involved in methadone metabolic pathway [7, 32] an influence of CYP2D6 
inhibitors was not expected. 
A genetic influence of CYP2B6*6 was observed on both enantiomers, with a more important 
effect on (S)-methadone. Its clearance is reduced by 37% in CYP2B6 Hom DOF carriers, 
whereas (R)-methadone clearance is decreased by 21%. These data confirm the 
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stereoselectivity of the CYP2B6 isoform for (S)-methadone, previously reported [8, 10-13, 17, 
33]. The lack of influence of CYP2B6*11 could be explained by its low minor allele frequency 
(0.8%). CYP2B6*5 was also not found to influence methadone elimination in agreement with 
an in vitro moderately decreased activity [33], despite the recent finding of its 
overrepresentation in a group of patients with low methadone concentration (thus suggesting 
an increased CYP2B6 activity) [22]. We therefore defined the CYP2B6 activity score by 
combining CYP2B6*6, *11 and *5, the major known DOF and loss of function (LOF) alleles of 
CYP2B6 in Caucasians.  
We report in the present study for the first time a decrease in methadone clearance in 
carriers of the CYP3A4*22 allele. This variant was previously shown to affect CYP3A4 
mRNA expression and enzyme activity, the mutant carriers presenting approximately 2.5-fold 
lower CYP3A4 activity [34], which was verified by CYP3A-phenotyping probes midazolam 
and erythromycin [35]. In univariate models, the CYP3A4*22 allele significantly decreased 
(R)-methadone clearance (-23%) and non-significantly (S)-methadone clearance (-15%). 
This small difference is most likely due to the stronger influence of CYP2B6 on (S)-
methadone rather than a real stereoselectivity of CYP3A4. The lack of CYP3A4 
stereoselective metabolism of methadone has been previously shown in vivo [7] and in vitro 
[8, 10, 11]. On the other hand, CYP3A5*3 did not seem to influence either (S)- or (R)-
methadone elimination, in accordance with in vitro [9] and in vivo results [7]. 
An increase in both enantiomers’ elimination in POR*28 Het or Hom carriers was observed in 
univariate analyses. This is in accordance with the increased CYP3A activity observed by 
midazolam phenotyping in POR*28 Hom GOF carriers [21, 36]. Conflicting results were also 
found [37, 38], which might suggest substrate specific-effects of POR variants on CYP3A 
activities [14]. In multivariate analyses, the influence of the POR*28 polymorphism was only 
observed for (R)-methadone, possibly due to the more important contribution of CYP2B6 to 
(S)-methadone thus masking the POR influence.  
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Methadone is a substrate and inhibitor of the PgP coded by the ABCB1 gene. We observed 
a small reduction in (S)-methadone clearance in carriers of one or two DOF alleles of the 
gene, whereas no effect was found for (R)-methadone. These results are in agreement with 
an in vitro experiment suggesting a weak stereoselectivity for the transport of the (S)-
enantiomer [39]. Moreover, a recent population pharmacokinetic study also found an 
association of ABCB1 2677G>T/A with a 20% reduction of the clearance of (R)- and (S)-
methadone, but did not observe any stereoselectivity [17]. 
The concentration-QTc relationship indicate that mean QTc is increased by 9.9 ms and 19.2 
ms per 1’000 ng/ml of (R)- and (S)-methadone, respectively, in line with  previously reported 
values of 17 ms for the racemate (CI90% 12-22) [15]. The magnitude of the effect is small and 
of modest clinical relevance at low methadone dosage. The range of QTc interval measured 
in our population was slightly higher than in the Framingham study [40] but did not include 
extreme QTc values, which might explain the modest concentration-effect relationship. Our 
results however suggest a more pronounced QTc increase with (S)-methadone, and confirm 
the more potent inhibition of the hERG channel by this enantiomer [4]. Considering that both 
enantiomers’ concentrations can increase in patients with a genetic-related poor elimination 
profile and the confirmed link between exposure and the risk of QTc prolongation, the need 
for caution is reinforced, especially at higher methadone dosage. This need for caution has 
been confirmed by recent studies on drug-induced QTc prolongation. A large study on the 
prevalence of drug-induced long QT in adult psychiatric patients reported that prolonged QTc 
was significantly associated with methadone, which was the most frequent drug among 
patients with drug-induced long QT [41]. Furthermore, among the reported 12 cases of 
sudden death and/or torsade de pointes (TdP), seven patients had received methadone. In 
another study aimed to determine the associated factors for prolonged QTc and the 
development of TdP, methadone was by far the leading medication implicated in the 
development of TdP and an independent predictor in both univariate and multivariate 
analyses despite the fact that it was not the most common QT-prolonging medication in their 
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population [42].   
 
One limitation of our study is that the relationships between both enantiomers and QTc could 
only be described with a linear relationship. QTc measurements were performed at two times 
post-drug intake, which prevented from the possibility to characterize the full 
pharmacokinetic-pharmacodynamic relationship and the relative increase in QTc interval 
after dose administration. Sex, calcium and potassium levels did not influence QTc in this 
study, neither did co-adminstration of drugs at risk for QT prolongation. Potassium and 
calcium levels were in the normal range, which might have limited to detect any association. 
Only few drugs with known risk of torsade de pointes were prescribed in this population and 
the influence of these drugs is expected to be modest within the normal range of QTc 
interval. Other patient’s risk factor, such as the use of illicit hERG blockers were not 
accounted for in our model, which is another study limitation. 
As previously reported [15], a simulation approach allowed to describe the concentration- QT 
interval relationship, while integrating for the first time genetic influence on methadone 
elimination. Patients carrying mutation of the CYP2B6*6 are at risk of exhibiting high 
methadone concentrations, in particular (S)-methadone, and QTc prolongation above the 
450 ms threshold. This risk is even more pronounced in case of additional variation such as 
CYP3A4*22 and ABCB1 3435C>T affecting (R)- and (S)-methadone elimination, 
respectively. Variation in the POR*28 would only partly compensate for a CYP2B6-
associated reduced (R)-methadone elimination.  
The ROC analysis predicted a threshold of 656 ng/ml (R,S)-methadone plasma 
concentration for QTc prolongation above 450 ms. This value should be considered 
cautiously as only 14 values of QTc  (among 317) were above 450 ms but is close to the 
clinically determined threshold of 800 ng/ml previously proposed [31].    
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Despite an important influence of CYP2B6 polymorphisms and other genes, the major part of 
methadone pharmacokinetic variability remains unexplained. The very large variability in 
plasma methadone concentrations renders the dose-concentration relationship difficult to 
predict. Plasma methadone concentrations measurements by therapeutic drug monitoring 
may be beneficial to guide practitioners’ dosing decisions, especially for those patients who 
have low levels despite high methadone doses or who are at risk of overdosing (i.e poor 
metabolizer status, high methadone dose or suspicion of a drug-drug interaction). As 
previously reported, trough plasma concentrations of 250 ng/ml for (R)-methadone or 
400ng/ml for (R,S)-methadone might be used as target values in cases of nonresponse [31]. 
Due to the widely unexplained pharmacokinetic variability and the fact that 
pharmacodynamic pathway–related genes in the heart and other factors such as electrolyte 
disturbances may also be important, our data confirm the need for electrocardiogram 
monitoring and arrhythmia risk factor assessment as determined in clinical practice for 
patients receiving doses above 100 or 120 mg/day [43, 44] or for unusual situation with 
trough (R,S)-methadone plasma concentrations above 660-800 ng/ml [31].  
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Legend to figures 
Figure 1 : (R)- and (S)-methadone plasma concentration-time profile (stratified for a 100 mg-
daily steady-state dose)(upper panels); QTc vs. time (middel panel) and observed 
concentration vs. QTc (lower panels), with population prediction (solid line) and 95% 
prediction interval (dashed lines).  
Figure 2 : Model-based predicted percentage of patients with QTC value above the threshold 
value of 450 ms (solid lines) and 470 ms (dashed lines) for different methadone daily doses 
and stratified according to the genetic effect for (A) (R)-methadone and (B) (S)-methadone. 
Black symbols: « best » (R)- or (S)-methadone clearance and white symbols: «lowest» (R)- 
or (S)-methadone clearance based on the final model estimates. For (S)-methadone, the 
“lowest” CL value is a CYP2B6 activity score of 0 (decrease of function allele; DOF) and 
ABCB1 3435 CC or CT (CL= 6.14 L/h) and the « best » CL value is a CYP2B6 activity score 
of 2 (reference allele; Ref) and ABCB1 3435 TT (CL=11.65 L/h). For (R)-Methadone, the 
“lowest” CL is a CYP2B6 activity score of 0 (DOF), POR*28 (homozygote gain of function 
allele; GOF) and CYP3A4*22 heterozygote DOF (CL=7.53 L/h) and the “best” CL is a 
CYP2B6 activity score of 2 (Ref), POR*28 Ref and CYP3A4*22 Ref (CL=10.97 L/h).  
Supplementary Figure 1: Goodness-of-fit plots for A : (R)-methadone and B : (S)-
methadone population and individual pharmacokinetic and QTc predictions vs observations 
and conditional weighted residuals (CWRES) vs. time after last dose. 
Supplementary Figure 2 : Receiver Operating Characteristic (ROC) curve indicating the 
best (R,S)-methadone plasma concentration threshold to predict a QTc prolongation above 
450 ms. *(R,S)-methadone plasma concentration value; sensitivity and specificity enclosed in 
parentheses. 
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Table 1: Demographic characteristics of the study population.  
 
Characteristic Value 
Sex (n=251) 
Men 
Women  
 
190 
61 
Age (years) (n=251) 
Mean ± SD 
 
36.4 ± 8 
Body weight (kg) (n=250) 
Mean ± SD 
 
77 ± 17 
Body Mass Index (kg/m2) (n=249) 
Mean ± SD 
 
25 ± 5 
-1 glycoprotein level (g/l) (n=181) 
Mean ± SD 
 
0.97 ± 0.31 
Methadone dose (mg/j) (n=251) 
Mean ± SD 
Median (range; interquartile range)
 
123 ± 75 
120 (3-400 ; 60-160) 
(R)-Methadone plasma concentrations 
(ng/ml) (n=507) 
Mean ± SD (range) 
Peak concentrations 1-5 h (ng/ml)  
Mean ± SD 
Trough concentrations 18-30 h (ng/ml)  
Mean ± SD 
 
 
 
267 ± 168 (11-1129) 
 
324 ± 184 (32-1129) 
 
222  ± 140 (11-874) 
(S)-Methadone plasma concentrations 
(ng/ml) (n=507) 
Mean ± SD (range) 
Peak concentrations 1-5 h (ng/ml)  
Mean ± SD 
Trough concentrations 18-30 h (ng/ml)  
Mean ± SD 

 
 
264 ± 172 (11-1123) 
 
344 ± 185 (47-1123) 
 
192 ± 128 (11-717) 
QTc interval  (ms) (n=317) 
Mean ± SD (range) 
At time=1-5 h (ms) 
At time=18-30 h (ms) 
 
422 ± 24 (348-466) 
410 ± 22 
413 ± 22 
Heart rate (bpm) (n=317) 
Mean ± SD 
 
71 ± 13 
Albumin (g/l)(n=184) 
Mean ± SD 
 
46 ± 5 
AST (U/l) (n=182) 
Mean ± SD 
 
58± 95 
ALT (U/I) (n=182) 
Mean ± SD 
 
69± 87 
-GT (U/l) (n=182) 
Mean ± SD 
 
73 ± 135 
Potassium levels (mmol/l) (n=182) 
Mean ± SD 
 
4.5 ± 0.41 
Total calcium levels (mmol/l (n=182) 
Mean ± SD 
 
2.3 ± 0.17 
 Abbreviations : AST, aspartate aminotransferase ; ALT, alanine amino transferase ;  -GT, gamma glutamyl 
transferase ; CYP, cytochrome P450. 
 
Comedications affecting the PK [26-27] 
CYP3A4 strong inhibitor: nefadozone (n=1) 
CYP3A4 weak inhibitors : efavirenz (n=2), fluoxetine (n=10), fluvoxamine (n=3), quetiapine (n=8), 
valproate (n=6), desogestrel and/or ethinylestradiol (n=2) 
CYP3A4 and CYP2B6 strong inducers : carbamazepine (n=1), efavirenz (n=2), St John’s wort (n=1) 
CYP3A4 weak inducers :  topiramate (n=10) 
CYP2B6 weak inhibitors : efavirenz (n=2) 
CYP2D6 strong inhibitors : bupropion (n=1), fluoxetine (n=10), paroxetine (n=10), levomepromazine 
(n=5), metoclopramide (n=2), thioridazine (n=4) 
CYP2D6 weak inhibitors : citalopram (n=9), escitalopram (n=12), fluvoxamine (n=3), haloperidol (n=1), 
hydroxyzine (n=1), nefadozone (n=1), quetiapine (n=8), risperidone (n=5), sertraline (n=4), venlafaxine 
(n=5) 
 
Comdedications affecting the QT [28] 
Known risk: haloperidol (n=1), astemizole (n=1), thioridazine (n=4) , citalopram (n=13) 
Possible risk: venlafaxine (n=5), olanzapine (n=15), mirtazapine (n=32), tizanidine (n=1), quetiapine 
(n=8), risperidone (n=4), aripiprazole (n=1), trimipramine (n=1). 
Conditional risk: paroxetine (n=10), chloral hydrate (n=10), fluoxetine (n=7), hydroxyzine (n=1), 
loperamide (n=1), pantoprazole (n=2), sertraline (n=4), amisulpride (n=3), doxepine (n=1). 
 
 
 
Co-Medication affecting the PK  
CYP3A4 strong inhibitors 
CYP3A4 weak inhibitor 
CYP3A4 and CYP2B6 strong inducers 
CYP3A4 weak inducers 
CYP2B6 weak inhibitors 
CYP2D6 strong inhibitors 
CYP2D6 weak inhibitors 
 
1 
31 
4 
10 
2 
32 
49 
Co-Medication affecting the QT 
Known risk of torsage de pointes  
Possible risk of torsde de pointes 
Conditional risk of torsade de pointes 
 
19 
67 
39 
 
 
Table 2 : Summary of the tested genetic polymorphisms in the study population (decrease or loss 
of function (LOF/DOF) and gain of function (GOF). 
 
Gene Alleles (Reference SNP) Ref (n) Het 
LOF/DOF (n)
Hom 
LOF/DOF (n) 
CYP2B6 *6 (*4 (rs2279343) and *9 
(rs3745274)) 
*5 (rs3211371) 
*11 (rs35303484)   
Intronic (rs2279344) 
intronic (rs8192719) 
146 
 
184 
240 
99 
145 
84 
 
57 
4 
114 
82 
14 
 
3 
0 
31 
17 
CYP2B6 
activity score# 
Combination of *5, *6, *11 143 86 15 
CYP2C9 *2 (rs1799853), *3 (rs1057910) 160 73 11 
CYP2C19 *2 (rs4244285), *3 (rs4986893) 169 63 12 
CYP2D6 *3 (rs35742686) ,*4 (rs3892097), 
*6 (rs5030655), *5 (gene deletion) 
 
121 108 11 
CYP3A4 *1B (rs2740574) 
*22 (rs35599367) 
223 
221 
20 
23 
1 
0 
CYP3A5 *3 (rs776746)§ 2§ 37§ 205§ 
CYP3A7 *1C (rs11568826 and 
rs11568825) 
226 18 0 
ABCB1  61A>G (rs9282564)°  201 36 7 
ABCB1 1199G>A (rs2229109)°  218 25 1 
ABCB1 1236C>T (rs1128503) 48 119 77 
ABCB1  2677G>T/A (rs2032582) 54 109 81 
ABCB1  3435C>T (rs1045642) 61 127 56 
     
  Ref (n) Het GOF (n) Hom GOF (n) 
POR *28 (rs1057868)°   133 106 12 
CYP2D6 *xN  11  
Abbreviations. LOF: loss of function; DOF: diminished function; GOF: gain of function; Ref: Reference, 
Het: heterozygote, Hom: homozygote.  
# Combination of CYP2B6*6, *5 and *11 alleles: a score of 2 (Ref) was attributed to fully functional alleles 
(CYP2B6 *1/*1, *1/*4, *1/*5, *4/*5, *5/*5), a score of 1 (Het LOF/DOF) to CYP2B6 *1/*11, *1/*6, *4/*6, 
*5/*6 and a score of 0 (Hom LOF/DOF) to CYP2B6 *6/*6 and *6/*11. 
§ Ref genotype corresponds to CYP3A5 *1/*1, Het LOF to CYP3A5 *1/*3 and Hom LOF to CYP3A5 *3/*3. 
° Effect might be substrate-dependant. 
 
Table 3: Final population pharmacokinetic and pharmacodynamics parameters for (R)- and (S)-methadone with  
the parameters obtained from the 2000 bootstrapped samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Final Population estimates  Bootstrap  (n=2000 samples) 
Parameters (R)-Methadone (S)-Methadone  (R)-Methadone (S)-Methadone 
Pharmacokinetics Estimate RSE (%) a Estimate RSE (%) a  Mean RSE (%) a Mean RSE (%) a 
ka (h-1)   0.46 --  0.85   0.46 -- 0.85 -- 
CL (L/h)   7.73 10% 7.31 12%  7.47 9% 7.27 12% 
Q (L/h)  79.8 6% 69.1 34%  81.6 12% 72.4 26% 
Vc (L) 105 18% 126 31%  102 25% 151 22% 
Vp (L) 655 15% 229 13%  774 43% 209 40% 
Tlag (h) 0.7 -- 0.39 --  0.7 -- 0.39  
AAG (L)  -- -- 0.23 12%  -- -- 0.24 25% 
CLCYP2B6 (L/h)  1.47 44% 3.10 15%  1.52 35% 3.06 15% 
CL POR*28 TT/CT (L/h)    1.33 40% -- --  1.32 40% -- -- 
CL ABCB1 3435 CC/CT(L/h)  -- -- -1.30 55%  -- -- -1.25 60% 
CL CYP3A4*22 TT/CT (L/h) -1.81 42%        
Pharmacodynamics   
Intercept (ms) 405 1% 407 1%  404 1% 406 1% 
Slope(ms/1000ng.ml-1) 9.9 36% 19.2 56%  11.2 41% 19.0 34% 
Interindivdiual variability (CV%)b    
ωCL  41% 4%c 51% 6%c  41% 6% 51% 6% 
ωVc 62% 19%c 71% 21%c  63% 18% 55% 22% 
Correlation CL-Vc 81% 19%c 74% 13%c  -- -- -- -- 
ωQ 37% 9% c 67% 31%c  38% 27% 76% 20% 
ωka -- -- -- --      
ωIntercept  4% 9%c 4% 7%c  4% 7% 4% 7% 
Intraindividual variability (CV %)d   
σconc. 25% 6%c 28% 17%c  6% 6% c 27% 13% 
σQT  3% 9%c 3% 7% c  3% 7% c 3% 16% 
Final model for (R)-methadone:	ܸܶܥܮ ൌ ܥܮ ൅ ߠ஼௅஼௒௉ଶ஻଺ ∙ √݊ 	 ൅ ߠ஼௅௉ைோ∗ଶ଼	்்/஼் 	൅	ߠ஼௅஼௒௉ଷ஺ସ∗ଶଶ	஼்		  ;  
and for (S)-methadone ܸܶܥܮ ൌ ܥܮ ൅ ߠ஼௅஼௒௉ଶ஻଺ ∙ √݊ 	൅ ߠେ୐	୅୆େ୆ଵ	ଷସଷହ	େେ/େ୘ 
 
Abbreviations: TV, typical population value; CL, clairance; Q intercompartmental CL; Vc and Vp, volume of distribution of the central et peripheral 
compartment, respectively; ka, absorption rate constant; Tlag, lag time in drug absorption; AAG, relative contribution of acid-glycoprotein (AAG) on the 
volume of distribution; CLCYP2B6, relative contribution of cytochrome 2B6 coded as an activity score (see text) on CL;  CL POR*28 TT/CT, relative contribution of 
cytochrome POR*28 heterozygotes and homozygotes on CL; θCL ABCB1 3435 CC/CT, relative contribution of ABCB1 3435 C>T heterozygotes and homozygotes on 
CL; θCL CYP3A4*22 CT; relative contribution of CYP3A4*22 heterozygotes on CL. 
a Relative standard error of estimates (RSE), calculated as SE/estimate.  
b Coefficient of variation, calculated as ඥ݁ሺఠమሻିଵ. 
c Relative standard error of the estimates, calculated as SE/RSE with SE= ሺܵܧሺఠమሻ/2√߱		ሻ	. 
d Coefficient of variation, calculated as ඥ݁ሺఙమሻିଵ. 
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